A recent study evaluating the effectiveness of the 2025-26 COVID-19 vaccine booster was initially rejected by the Centers for Disease Control and Prevention’s (CDC) own journal before being published in an external medical journal, raising questions about the agency’s approach to vaccine research and public communication.

The study, led by a collaborative group involving the CDC and multiple health systems including Kaiser Permanente, Intermountain Health, and Columbia University, analyzed data from over 100,000 adults who sought care for respiratory illnesses between September and December 2025. Researchers found that the updated booster reduced COVID-19-related emergency department visits by 50 percent and hospitalizations by 55 percent. These results were consistent with prior years’ findings and aligned with independent research from five European countries, which documented a 59 percent reduction in healthcare visits for symptomatic COVID-19 among older adults shortly after vaccination, though protection waned over time.

Despite its robust data and established methodology, the study’s planned publication in the CDC’s Morbidity and Mortality Weekly Report (MMWR) was delayed and ultimately blocked by acting CDC director Jay Bhattacharya. Bhattacharya’s objection centered on the study’s use of the “test-negative” design, a common epidemiological method for assessing vaccine effectiveness. This design compares vaccination status between patients who seek medical care for respiratory symptoms and test positive for the virus to those who test negative.

While the test-negative approach does not match the rigor of long-term cohort studies, it allows for timely evaluation of vaccine performance amid evolving viral strains—a critical advantage for respiratory viruses like COVID-19 and influenza. This methodology has been employed widely for decades and is recognized for its practical application in real-world settings despite acknowledged limitations.

The controversy has drawn attention to several concerns. First, delaying the study’s publication hindered the timely dissemination of crucial information needed to guide public health decisions and individual choices about vaccination during the 2025-26 season. The MMWR’s mission is to provide rapid communication of data with immediate public health relevance, and withholding the findings potentially affected vaccine uptake earlier in the year.

Second, the incident occurs amid broader shifts in federal vaccine policy. Earlier in 2026, the Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr. removed universal immunization recommendations for six childhood diseases and replaced all members of the CDC’s vaccine advisory committee. Kennedy, known for his critical stance on COVID-19 vaccines, has been reshaping vaccine governance and influencing access policies. These developments have fueled speculation that scientific objections to the study’s methodology may mask opposition to its positive findings.

Third, if the CDC moves away from the test-negative design to evaluate vaccines, it could disrupt ongoing surveillance and assessment of vaccine effectiveness for common respiratory infections. Given the approach’s central role in public health research, its rejection could complicate future vaccine recommendations and undermine confidence in vaccine monitoring processes.

The ultimate publication of the study in an independent journal has preserved important evidence supporting booster use, but the contentious review process highlights tensions between scientific rigor, public health priorities, and policy influences shaping vaccine research and communication at the CDC.